Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Proof of Concept Study to Isolate Cosmetic Improvement of Skin Using the Vitro Biopharma Secretome/Exosome Serum

26 de mayo de 2026 actualizado por: Vitro Biopharma Inc.

Proof of Concept Split-Face Single-Blind Study to Assess the Cosmetic Appearance of Skin on Subjects Using the Vitro Biopharma Secretome/Exosome Serum

The purpose of this research is to characterize the safety, tolerability and efficacy of the investigational topical cosmetic product, the Vitro Biopharma Exosome Serum (Intervention), in impacting the cosmetic appearance of skin along with a microneedling procedure.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

7

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Estados Unidos
    • Massachusetts
      • Chestnut Hill, Massachusetts, Estados Unidos, 02467
        • SkinCare Physicians

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Male or female subjects over 30 years of age
  • Non-smoker
  • Fitzpatrick scale II-IV
  • Mild to moderate skin wrinkles or fine lines around the eyes (periorbital) and/or radial cheek
  • Subject agrees to maintain their weight (i.e. within 5%) by not making any major changes in diet of lifestyle during study
  • Able to provide written informed consent, understand and willing to comply with study related procedures and follow-up
  • Willing to undergo facial microneedling treatment
  • Willing to sign photo release (For study purposes and potential publication)

Exclusion Criteria:

  • Prior trauma, surgical procedure or invasive cosmetic procedure in the area of intended treatment
  • Fat reduction/removal procedure in or around the area of intended treatment up to 1 year prior to enrollment
  • Cosmetic injections into the area of intended treatment including botulinum toxin injections up to 6 months prior or filler injections up to 1 year prior to enrollment
  • Ablative or non-ablative dermal resurfacing procedures within 6 months of screening
  • Skin tightening procedures on the face within the past 3 months
  • Currently using prescription facial wrinkle therapies
  • History of bleeding disorder, or is taking any medication that may increase risk of bruising
  • Dermatological conditions in the location of the treatment sites that may interfere with treatment
  • Subject has an active infection
  • Subject has a known metal allergy
  • Pre-existing scars, tattoos, birthmarks or other physical features in the area of treatment that may confound the outcome in the investigators opinion
  • Active implanted device such as pacemaker, defibrillator, drug delivery system
  • Pregnant or intending to become pregnant
  • Lactating or has been lactating in the last 6 months
  • History of coagulopathy, or taking anticoagulants
  • Taking daily oral aspirin
  • Immunocompromised or immunosuppressed
  • Active, chronic or recurrent infection
  • Hypersensitivity to analgesic agents
  • History of keloid scar formation
  • Chronic disease such as diabetes, hepatitis, etc.
  • Oral corticosteroids or topical steroids in the treatment area
  • Prescription or over the counter (OTC) medication or cosmetics applied to treatment area containing: retinoids, glycol acid, salicylic acid or any other remedies that might affect the healing process.
  • Co-morbid condition that could limit ability to participate in the study or comply with follow-up requirements
  • Untreated drug and/or alcohol abuse
  • Unable or unwilling to comply with the study requirements
  • Enrolled in another clinical study or taking any unknown or not Food and Drug Administration (FDA) approved medications
  • Any other condition or presentation that in the opinion of the Investigator might exclude the subject
  • Intends to begin any new skin medications in the treatment areas
  • Intends to change their daily skincare routine before or during the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention v Control
Otro: Secretome/Exosome Serum
The Vitro Biopharma Exosome Serum contains extracellular vesicles derived from umbilical cord MSCs

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Procedure-Related Adverse Events by Symptom and Severity
Periodo de tiempo: Procedure Day through Day 90 follow-up (assessments at 1 hour, Day 1, 7, 21, 45, 46, 52, 66, and 90)
Adverse events related to the procedure (microneedling with or without Vitro Biopharma Exosome Serum) will be assessed at each in-person follow-up visit using the Clinical Safety Assessment (Protocol Appendix D). Physician-assessed events include erythema, edema, and scabbing/peeling/dry skin. Subject-reported events include pain, pruritis, paresthesia, and discomfort. Each event will be recorded as present or absent with severity graded as Mild, Moderate, or Severe. Number of participants with each event by severity grade will be reported for each treatment side.
Procedure Day through Day 90 follow-up (assessments at 1 hour, Day 1, 7, 21, 45, 46, 52, 66, and 90)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference Between Intervention and Control Sides in Incidence of Anticipated Microneedling-Related Adverse Events
Periodo de tiempo: Post-procedure Days 1, 7, 21, and 45 on each treatment side (study Days 1, 7, 21, 45 for control; study Days 46, 52, 66, 90 for intervention)
For each anticipated microneedling-related event (erythema, edema, scabbing/peeling/dry skin, pain, pruritis, paresthesia, discomfort) defined in Protocol Appendix D, the number of participants reporting the event on the intervention (Exosome Serum) side will be compared to the number reporting the event on the control (no Exosome Serum) side at matched post-procedure time points.
Post-procedure Days 1, 7, 21, and 45 on each treatment side (study Days 1, 7, 21, 45 for control; study Days 46, 52, 66, 90 for intervention)
Change from Baseline in Global Aesthetic Improvement Scale (GAIS) Score by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live assessment); post-Day 90 image-based assessment
Aesthetic improvement of each treatment area relative to baseline images will be rated by a blinded evaluator using the 5-point GAIS (1 = Exceptional Improvement, 2 = Very Improved, 3 = Improved, 4 = Unaltered, 5 = Worsened). Mean GAIS score will be reported per treatment side at each assessment, and the difference between intervention and control sides will be reported.
Day 45 and Day 90 follow-up (live assessment); post-Day 90 image-based assessment
Change from Baseline in Transepidermal Water Loss (TEWL)
Periodo de tiempo: Time Frame: Pre-Treatment (baseline) and follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90
TEWL will be measured at each treatment area using a topical probe with temperature and relative humidity sensors, reported in g/m²/h. Mean change from baseline at each post-procedure time point and the difference between intervention and control sides will be reported.
Time Frame: Pre-Treatment (baseline) and follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90
Change from Baseline in Subject-Reported Clinical Global Impression-Improvement (CGI-I) Score
Periodo de tiempo: Follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90
At each follow-up visit, subjects will rate overall appearance of each treatment area compared to before the procedure using the CGI-I (1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, 7 = Very Much Worse), per Protocol Appendix F. Mean score per side at each time point and the between-side difference will be reported.
Follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Skin Radiance on the Modified Griffiths 10-Point Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Skin radiance improvement on each treatment area will be rated by a blinded evaluator using the Modified Griffiths 10-point scale (0 = No Improvement; I to III = Mild; IV to VI = Moderate; VII to IX = Best Improvement), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Skin Tone Evenness on the Modified Griffiths 10-Point Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Skin tone evenness on each treatment area will be rated by a blinded evaluator using the Modified Griffiths 10-point scale (None (0); Mild (I to III); Moderate (IV to VI); Severe (VII to IX) unevenness of red/brown patches or spots), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Surface Roughness on the Allergan Skin Roughness Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Visual surface roughness on each treatment area will be rated by a blinded evaluator using the Allergan Skin Roughness Scale (0 = None, 1 = Minimal, 2 = Moderate, 3 = Severe, 4 = Extreme), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Cheek and Midface Wrinkle Severity on the Allergan Fine Lines Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Cheek and midface fine line severity on each treatment area will be rated by a blinded evaluator using the Allergan Fine Lines Scale (0 = None, 1 = Minimal, 2 = Moderate, 3 = Severe, 4 = Diffuse), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Periorbital Wrinkle Severity at Rest on the Merz Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Periorbital wrinkle severity at rest on each treatment area will be rated by a blinded evaluator using the Merz Scale (0 = No Wrinkles, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Dynamic Periorbital Wrinkle Severity (Smiling) on the Merz Scale by Blinded Evaluator
Periodo de tiempo: Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Periorbital wrinkle severity while smiling on each treatment area will be rated by a blinded evaluator using the Merz Scale (0 = No Wrinkles, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe), per Protocol Appendix G. Mean score per side and between-side difference will be reported.
Day 45 and Day 90 follow-up (live); post-Day 90 image-based assessment
Change from Baseline in Skin Viscoelasticity by Cutometer Measurement
Periodo de tiempo: Pre-Treatment (baseline) and follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90
Mechanical/viscoelastic properties of the skin will be measured at each treatment area using a Cutometer, reported as the R2 (gross elasticity) parameter. Mean change from baseline at each post-procedure time point and the difference between intervention and control sides will be reported.
Pre-Treatment (baseline) and follow-up Days 1, 7, 21, 45, 46, 52, 66, and 90
Change from Baseline in Subject Satisfaction with Facial Skin Attributes (5-Point Likert Scale)
Periodo de tiempo: Baseline (pre-procedure) and Day 90 follow-up
Subjects will rate satisfaction with five facial skin attributes (presence of wrinkles under the eyes, presence of wrinkles on the cheeks, smoothness, radiance/brightness, and tone evenness) on a 5-point Likert scale (1 = Very Satisfied, 2 = Somewhat Satisfied, 3 = Neither Satisfied nor Dissatisfied, 4 = Somewhat Dissatisfied, 5 = Very Dissatisfied) at baseline (Protocol Appendix E) and at final follow-up (Protocol Appendix H) for each treatment side. Mean change per attribute per side and between-side difference will be reported.
Baseline (pre-procedure) and Day 90 follow-up
Number of microRNAs (miRNAs) Demonstrating Consistent Directional Change in Expression on the Intervention Side Compared to the Control Side by NanoString miRNA Profiling
Periodo de tiempo: Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Punch biopsies of periauricular skin obtained pre-procedure (baseline), post-control side procedure, and post-intervention side procedure will undergo RNA extraction and miRNA expression profiling by NanoString miRNA technology at a blinded contract laboratory. Raw Reporter Code Count (RCC) files will be background-normalized using negative-control probe thresholds, and low-expressing miRNAs will be removed. Percent-change from baseline will be calculated separately for the control and intervention sides. A tiered filtering algorithm will identify miRNAs meeting cross-subject directional consistency and a magnitude threshold on the net-effect calculation. The total number of miRNAs meeting these pre-specified criteria will be the reported endpoint. Descriptive breakdowns of the identified miRNAs will be reported in tables.
Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Histologic Assessment of Elastic Fiber Architecture in Skin Biopsy (Van Gieson Stain) by Blinded Dermatopathologist
Periodo de tiempo: Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Punch biopsies of periauricular skin will be obtained pre-procedure (baseline), 30 to 45 days post-control side procedure, and 30 to 45 days post-intervention side procedure. Sections will be stained with Van Gieson and evaluated by a board-certified dermatopathologist blinded to treatment assignment. Elastic fiber architecture in the papillary dermis on the intervention side will be categorized relative to the matched control side as increased, unchanged, or decreased. The number of subjects in each directional category will be reported.
Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Histologic Assessment of Collagen Fiber Density and Organization in Skin Biopsy (Masson's Trichrome Stain) by Blinded Dermatopathologist
Periodo de tiempo: Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Punch biopsies of periauricular skin will be obtained pre-procedure (baseline), 30 to 45 days post-control side procedure, and 30 to 45 days post-intervention side procedure. Sections will be stained with Masson's Trichrome and evaluated by a board-certified dermatopathologist blinded to treatment assignment. Collagen fiber density and organization on the intervention side will be categorized relative to the matched control side as increased, unchanged, or decreased. The number of subjects in each directional category will be reported.
Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Histologic Assessment of Vascular Density in Skin Biopsy (H&E Stain) by Blinded Dermatopathologist
Periodo de tiempo: Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)
Punch biopsies of periauricular skin will be obtained pre-procedure (baseline), 30 to 45 days post-control side procedure, and 30 to 45 days post-intervention side procedure. Sections will be stained with hematoxylin and eosin (H&E) and evaluated by a board-certified dermatopathologist blinded to treatment assignment. Vascular density on the intervention side will be categorized relative to the matched control side as increased, unchanged, or decreased. The number of subjects in each directional category will be reported.
Pre-procedure (baseline); 30 to 45 days post-control side procedure (study Days 30 to 45); 30 to 45 days post-intervention side procedure (study Days 75 to 90)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Vitro Biopharma Inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de abril de 2024

Finalización primaria (Actual)

30 de enero de 2025

Finalización del estudio (Actual)

30 de enero de 2025

Fechas de registro del estudio

Enviado por primera vez

13 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de mayo de 2026

Publicado por primera vez (Actual)

2 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • Vitro Biopharma 001 (VB001)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Only the individual participant data (IPD) used in the results publication will be shared.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir